|
|
|
|
 |
Regulus Therapeutics to Host Conference Call to Discuss GlaxoSmithKline Alliance |
| Companies mentioned in this article: |
|
Isis Pharmaceuticals |
|
| 4/17/2008 @ 7:37 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will hold a conference call this morning, Thursday, April 17, at 8:00 a.m. ET to discuss its new alliance with GlaxoSmithKline.
Conference Call Information
The call may be accessed by dialing 866-362-4820 (domestic) or 617-597-5345 (international) five minutes prior to the start time, and providing the passcode 80836102. A replay of the call will be available from approximately 10:00 a.m. ET April 17, 2008 until April 24, 2008. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international), and provide the passcode 18930576. A live audio webcast of the call will also be available on the “Investors” section of the Alnylam and Isis company websites, www.alnylam.com and www.isispharm.com. An archived webcast will be available on both websites approximately two hours after the event, and will be archived for 14 days thereafter.
About Regulus Therapeutics LLC
Regulus is a biopharmaceutical company formed to discover, develop and commercialize microRNA therapeutics. Regulus was founded in late 2007 as a joint venture between Alnylam Pharmaceuticals, a leader in RNAi therapeutics, and Isis Pharmaceuticals, a leader in antisense technologies and therapeutics. Isis and Alnylam scientists and collaborators were the first to discover microRNA antagonist strategies that work in vivo in animal studies (Krutzfeldt et al. Nature 438, 685-689 (2005); Esau et al. Cell Metab., 3, 87-98 (2006)). Isis and Alnylam have also created and consolidated key intellectual property for the development and commercialization of microRNA therapeutics. Regulus maintains facilities in Carlsbad, California. For more information, visit www.regulusrx.com.
About Alnylam Pharmaceuticals, Inc.
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is leading the translation of RNAi as a new class of innovative medicines with peer-reviewed research efforts published in the world’s top scientific journals including Nature, Nature Medicine, and Cell. The company is leveraging these capabilities to build a broad pipeline of RNAi therapeutics; its most advanced program is in Phase II human clinical trials for the treatment of respiratory syncytial virus (RSV) infection. In addition, the company is developing RNAi therapeutics for the treatment of influenza, hypercholesterolemia, and liver cancers, among other diseases. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Medtronic, Novartis, Biogen Idec, and Roche. The company, founded in 2002, maintains headquarters in Cambridge, Massachusetts. For more information, visit www.alnylam.com.
About Isis Pharmaceuticals, Inc.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis’ drug development programs are focused on treating cardiovascular and metabolic diseases. Isis’ partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis’ majority-owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com. |
| BioTech / BioMedical / Medical |
|
|
| |
| Tuesday, July 8, 2008 |
 |
|
International Stem Cell Corporation Announces Collaboration with Michigan State University to Study Parthenogenetic Stem Cells Posted 7:47 AM PST
FDA Grants Invitrogen Premarket Approval of Breast Cancer Test Posted 7:42 AM PST
|
| |
| Monday, July 7, 2008 |
|
|
Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV Posted 3:06 PM PST
AutoGenomics INFINITI Analyzer Receives Artistic Design Award Posted 6:35 AM PST
|
| |
| Wednesday, July 2, 2008 |
|
|
PainReform Licenses a Novel Sustained Release Formulation of Ropivacaine from Encore Therapeutics Inc. Posted 6:37 AM PST
Sequenom Launches iSEQ Application Posted 6:36 AM PST
Sequenom Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares Posted 6:36 AM PST
PURE Bioscience Strengthens Pharmaceutical Development Program Posted 6:33 AM PST
MicroIslet Provides Safety and Efficacy Data Update; No Adverse Events Attributable To MicroIslet-P In Animal Models Posted 6:31 AM PST
|
| |
| Tuesday, July 1, 2008 |
|
|
Metabasis to Present at the Collins Stewart 4th Annual Growth Conference Posted 4:34 PM PST
ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor Posted 1:35 PM PST
The Wellcome Trust Case Control Consortium (WTCCC) Selects Illumina Infinium High-Density (HD) DNA Analysis Products to Study 90,000 Samples Posted 8:04 AM PST
Aethlon Medical Announces Second HIV/AIDS Treatment Site Posted 8:03 AM PST
|
| |
| Monday, June 30, 2008 |
|
|
Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial Posted 3:11 PM PST
Invitrogen and the Génome Québec and Montreal Heart Institute Pharmacogenomics Centre Announce Collaboration to Advance Pharmacogenomics Research Posted 2:52 PM PST
Burnham Institute Researchers Link Early Stem Cell Mutation to Autism Posted 2:51 PM PST
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 Posted 6:46 AM PST
Cardium Announces Follow-On Direct Investment by Institutional Investor Posted 6:41 AM PST
Early Results from Ongoing Clinical Study of Hepatitis C Vaccine Delivered by Inovio Biomedical’s Electroporation System Show Increased T-Cell Responses and Reduced Viral Loads Posted 6:31 AM PST
|
| |
| Wednesday, June 25, 2008 |
|
|
$6 Million Grant from NIH Advances Vical RapidResponse DNA Vaccine Platform Posted 8:55 AM PST
Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing Posted 8:49 AM PST
Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients Posted 8:49 AM PST
International Stem Cell Corporation Cuts a Deal with BioTime, Inc., and Embryome Sciences, Inc., to Provide Unique Human Stem Cell Lines for Research Use Posted 8:08 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
